Optrex Allergy

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Optrex Allergy

What is Optrex Allergy?

Optrex Allergy is a medicated ophthalmic solution designed to provide relief from the symptoms of allergic conjunctivitis. It is formulated to target the underlying mechanisms of ocular allergies, which often manifest when the eyes react to environmental triggers such as pollen, pet dander, mold spores, or dust mites.

Active Ingredient and Mechanism

The primary active component in Optrex Allergy eye drops is sodium cromoglicate. This substance belongs to a class of medications known as mast cell stabilizers. Unlike antihistamines, which block the action of histamine after it has been released, mast cell stabilizers work by preventing the mast cells in the conjunctiva from rupturing and releasing inflammatory chemicals.

When an individual with an allergy is exposed to an allergen, their immune system may trigger mast cells to release histamine and other mediators. These substances cause the characteristic symptoms of an allergic reaction, including inflammation, redness, and itching. By stabilizing the cell membrane, sodium cromoglicate helps to inhibit this initial response.

Clinical Application

Optrex Allergy is used to manage several types of allergic eye conditions:

  • Seasonal Allergic Conjunctivitis: Often referred to as hay fever, this condition occurs at specific times of the year when pollen counts from trees, grasses, or weeds are high.
  • Perennial Allergic Conjunctivitis: This persists throughout the year and is typically caused by indoor allergens like household dust or animal fur.

Characteristics of the Solution

The formulation is a clear, aqueous solution intended for topical application directly to the eye. It is designed to act locally on the ocular surface to reduce swelling and irritation. Because its mechanism involves stabilizing cells before they release inflammatory mediators, the solution is often most effective when used consistently during periods of allergen exposure.

Regulatory References

  1. NIH StatPearls article on Cromolyn Sodium

What side effects are possible with Optrex Allergy?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of Sodium Cromoglicate ophthalmic solution as documented in official government regulatory documents.

Adverse Reaction Classification

The safety profile is heavily characterized by events that occur locally at the site of administration, with minimal systemic involvement. The most frequently reported adverse reactions are classified as transient (short-lived) local effects.

Classification System-Organ Class Examples of Documented Effects
Most Frequently Reported Eye Disorders Transient ocular stinging, transient burning, transient blurred vision immediately following instillation.
Rare Eye Disorders Eye irritation, conjunctival injection (redness), dryness, increased tearing, or styes.
Extremely Rare Immune System Disorders Immediate hypersensitivity reactions, including swelling (edema) or difficulty breathing (dyspnea), and anaphylaxis.

Safety Considerations

The regulatory safety profile includes specific population and constraint notes. Safety and efficacy are not established in pediatric patients below the age of four years. For pregnant and lactating women, official documentation advises use only where there is a clear need, based on the low likelihood of systemic exposure. A specific safety restriction relates to the excipient Benzalkonium Chloride (a common preservative), which may cause eye irritation or affect the corneal surface, especially in individuals with pre-existing dry eye conditions. Transient blurred vision following instillation may temporarily interfere with the ability to drive or operate machinery until vision is restored.

Overdose and Emergency Response

Overdose Scope: Official Regulatory Summary

Feature Regulatory Documentation Statement
Documented overdose presentations Overdosage is very unlikely due to the extremely poor systemic absorption from both the ocular surface and the gastrointestinal tract upon accidental ingestion.
Physiological systems affected (as stated in label) No specific systemic effects or life-threatening outcomes are documented in official regulatory labels for overdose of the ophthalmic solution.
Dose-related or exposure-related factors (if applicable) The compound's low systemic bioavailability (approx. 1% following ingestion and less than 0.03% via the eye) is the basis for the low risk classification.
Population-specific overdose notes (if applicable) None are explicitly documented in the regulatory overdose sections.
Emergency-response statements (as written in official documents) Individuals must contact their regional poison control centre for management of a suspected drug overdose.
When immediate medical help is required (label-derived phrasing only) If the solution is accidentally ingested, an individual must talk to their doctor or pharmacist or go to the hospital straight away.

Overdose Classifications (High-Level)

Classification Feature Regulator-Derived Statement
Severity classification (as defined in official documents) Overdosage is considered to have a low risk of systemic toxicity by regulatory bodies.
Regulatory basis (EMA / FDA / etc.) Information derived from multiple official government regulatory prescribing information sources (SmPC / FDA / Health Canada).
Overdose-context constraints (as defined in official documents) Medical observation is the primary management recommendation, indicating low-level clinical concern for systemic effects.

Resulting Overdose Structure

Official overdose statements:

  • Overdosage is formally classified as very unlikely because of the active ingredient's minimal systemic absorption.
  • No specific antidote is mentioned in the official prescribing information, and no specific systemic manifestations are listed as expected following over-exposure.
  • Medical observation is recommended in all cases of suspected overdose, as per the Summary of Product Characteristics (SmPC).
  • Urgent action is explicitly required only if the ophthalmic solution is accidentally ingested, necessitating immediate contact with a poison control centre or hospital.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by emphasizing the drug's limited systemic absorption, which establishes a low risk of serious systemic toxicity. Consequently, the official management is primarily symptomatic and supportive. Authorities nevertheless mandate that urgent medical help must be sought immediately following accidental ingestion of the solution, despite the low expected systemic effect.

Therapeutic Uses of Optrex Allergy

The medication is used in situations involving certain distressing symptoms linked to ocular allergy. The ophthalmic solution is applied across domains where additional symptomatic support is needed for managing the symptoms of allergic conjunctivitis. It is used for managing the symptoms of this condition, relevant for easing manifestations such as eye itching, watering, and redness. This use contributes to easing the overall symptom load.

For Symptom Management of Seasonal and Perennial Allergies

It is commonly used across conditions presenting with episodic or fluctuating manifestations, centering on seasonal conditions like hay fever, or perennial symptoms related to continuous exposure to indoor allergens. This provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Ocular Discomfort

This medication is generally used to help manage symptoms that create noticeable functional strain in relevant patient groups, including adults and children. It is often used during phases when symptoms become more noticeable and supports patients during difficult episodes by easing distress related to the symptoms associated with inflammatory or irritative states.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Optrex Allergy — Official Regulatory Information

The eligibility for Optrex Allergy (Sodium Cromoglicate Ophthalmic Solution) is defined by official regulatory documents, establishing clear population boundaries for its use.

Populations for whom use is allowed (as stated in label):

  • Adults, including the elderly population.
  • Children and adolescents aged 6 years and over.

Populations for whom use is contraindicated:

  • Patients with known hypersensitivity to the active substance, sodium cromoglicate, or to any of the listed excipients in the formulation.

Age-related eligibility rules:

  • The medicine is not recommended for use in children under 6 years of age.

Pregnancy and lactation eligibility status (if explicitly documented):

  • Pregnancy: Use is advised with caution, especially during the first trimester. It should be used only where there is a clear need.
  • Lactation: Caution should be exercised when administered to a nursing mother.

Eligibility-related restrictions:

  • Individuals who wear soft contact lenses must remove them before application and should not wear them during the treatment period, due to the presence of the preservative benzalkonium chloride.

Connection to the overall eligibility profile: Regulatory documents establish that the drug is eligible for use by the general population over the age of six, but they impose absolute prohibitions based on known ingredient sensitivity and require caution or specific restrictions for soft contact lens wearers, pregnant or breastfeeding individuals, and children below the minimum age threshold.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents indicate that no formal interaction studies have been performed for Optrex Allergy (Sodium Cromoglicate) eye drops. Therefore, the product's official interaction profile is defined by two key areas: general caution regarding concurrent medicines and a specific restriction concerning a non-medicinal device.


Interaction Scope Summary

Product Category Interaction Type Regulatory Constraint
Other Medicines General Caution Advised to inform a healthcare professional before use.
Soft Contact Lenses Excipient Absorption Must be removed prior to application.

Official Interaction Statements

  • General Medicinal Products: You must inform a doctor or pharmacist if you are taking, have recently taken, or might take any other medicines before using this product. The official information does not list any specific drug-drug combinations that are contraindicated or require dose adjustment.
  • Soft Contact Lenses: The excipient benzalkonium chloride in the eye drops may cause eye irritation and is known to be absorbed by soft (hydrophilic) contact lenses. This absorption carries the potential to change the color of the lenses.
  • Timing Constraint: To mitigate the interaction with soft contact lenses, the lenses must be removed immediately prior to the application of the drops, and reinsertion should be delayed for a minimum of 15 minutes following drop instillation.

The regulatory structure emphasizes that the most significant documented constraint is the procedural requirement involving soft contact lenses, due to the excipient. Aside from this, official documentation requires disclosure of concurrent medicine use without specifying clinically significant drug-drug interactions for this product.

Mechanism of Action

Optrex Allergy, containing sodium cromoglicate, is classified as a mast cell stabilizer. Following topical ocular administration, the compound interacts selectively with mast cells residing in the conjunctival tissue. The precise molecular target is not fully elucidated but involves the inhibition of a complex intracellular signaling cascade initiated by allergen-mediated IgE receptor cross-linking on the mast cell surface.

This interaction results in the stabilization of the mast cell membrane, primarily through the indirect blockade of calcium ion influx necessary for cellular activation. By maintaining the integrity of the mast cell membrane, sodium cromoglicate prevents the subsequent process of degranulation (exocytosis). This inhibitory action modulates the release of pre-formed inflammatory mediators, including histamine, and inhibits the de novo synthesis of other lipid mediators like leukotrienes and prostaglandins. The downstream cascade involves a reduction in the local concentration of these potent chemical signals within the ocular microenvironment, leading to systemic physiological modulation by limiting mediator-driven cellular responses such as microvascular permeability and vasodilation.

Dosage and Administration Information

Application Procedure

To apply the eye drops, the head should be tilted back and the lower eyelid gently pulled down to create a small pocket. The dropper tip is held above the eye without making direct contact with the eye surface, eyelashes, or any other objects. One drop is released into the pocket, and the eye should be closed for a brief period to allow the solution to spread across the ocular surface.

If the drops are being used in both eyes, the process is repeated for the second eye. To prevent contamination of the solution, the cap must be replaced firmly immediately after use.

Usage with Contact Lenses

Standard ocular solutions containing preservatives may interact with soft contact lenses. Generally, lenses should be removed prior to the application of the drops. A period of at least 15 minutes is typically observed before reinserting the lenses to ensure the solution has been fully absorbed or cleared from the ocular surface.

General Handling and Storage

Proper hygiene is maintained by washing hands thoroughly before and after handling the bottle. The container is designed for individual use to minimize the risk of cross-contamination between users.

The product should be stored according to the temperature requirements specified on the packaging, usually away from direct sunlight and heat. Once the bottle has been opened, the solution remains viable for a limited duration, after which any remaining liquid must be discarded.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Optrex Allergy

Evidence for Use in Seasonal and Perennial Eye Allergies (SAC/PAC)

Research involving Sodium Cromoglicate ophthalmic solution was studied for its relevance in trials assessing short-term or episodic symptom patterns, specifically in conditions characterized by fluctuating or episodic manifestations, such as seasonal and perennial allergic conjunctivitis. The primary research approach has involved short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies explored adults and children over the age of six.

Research examined outcomes related to physical discomfort, specifically focusing on patient-reported outcomes describing perceived discomfort. These include the intensity of ocular itching, eye watering, and redness. The findings describe patterns observed in the studies where, in groups receiving Sodium Cromoglicate, the research examined the difference in changes measured in symptoms between these groups and the placebo groups. This evidence provides context but not individual predictions regarding symptom patterns in conditions involving periods of heightened symptoms.

Research Exploring Long-Term Patterns and Follow-up

Evidence for long-term use remains limited compared to data focusing on short-term outcomes. The majority of the clinical research is relevant in trials assessing short-term or episodic symptom patterns, with follow-up durations were limited to the acute treatment phase. There is limited information for long-term outcomes that would provide definitive insight into sustained benefit or patterns of use over many years. The findings describe group patterns, not personal outcomes, and should be viewed within the context of the short study periods.

Understanding the Research Limitations

It is important to acknowledge that the research base has several acknowledged limitations. Sample sizes were modest in many of the older studies, and evidence quality varies across studies due to differences in methodology and symptom measurement. Comparative evidence is lacking in some areas, particularly concerning modern comparisons against other available eye drop formulations. The results apply only to the populations studied and the specific conditions under which they were conducted. Therefore, evidence highlights what is known—and what is still uncertain—about this medication.

Key Studies & References

  1. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness
  2. Allergic Conjunctivitis (NIH StatPearls)

Frequently Asked Questions (FAQ)

Common questions about Optrex Allergy (FAQ)

Q: How quickly does Optrex Allergy start working after I use it?

A: Official information indicates that the symptomatic response to this type of therapy may become evident within a few days of starting treatment. However, consistent and regular use over a period of time may be necessary to realize the medication's maximum benefit.


Q: How long do the effects of Optrex Allergy last?

A: The eye drops are typically administered four times a day at regular intervals, according to official administration instructions. This frequency is intended to maintain a consistent presence of the medicine at the application site throughout the day.


Q: Can Optrex Allergy drops cause dry eyes over time?

A: Dry eyes or eye irritation are listed in official product information as rare local side effects following instillation. The preservative benzalkonium chloride is noted as a component that may cause irritation, especially for individuals with pre-existing dry eye conditions.


Q: Is Optrex Allergy safe to use during pregnancy?

A: Official regulatory documentation advises using this medicine during pregnancy only where there is a clear need. The decision to use the product during pregnancy requires consultation with a healthcare professional, as advised in official patient information.


Q: What is stated about using Optrex Allergy while breastfeeding?

A: It is not known whether the active medicine passes into human milk. Due to this uncertainty, official product information states that caution should be exercised when the eye drops are used by a nursing mother.


Q: What if I accidentally put the drops in my mouth or swallow a small amount?

A: The active ingredient, sodium cromoglicate, is poorly absorbed by the body if swallowed. In the event of accidental ingestion, official documents reference the need for consultation with a doctor or pharmacist.


Q: Can I use Optrex Allergy with other eye drops, and if so, how far apart?

A: When using other eye drops or ointments, administration instructions generally recommend waiting at least 5 minutes between the application of each separate product. This spacing procedure is generally followed to allow for proper administration and retention of each medicine on the eye surface.


Q: Is Optrex Allergy available over the counter?

A: Yes, Optrex Allergy is typically classified as an Over-The-Counter (OTC) medicine in its primary markets. This means it can generally be purchased without needing a prescription.


Q: Does Optrex Allergy help with all types of eye allergies?

A: Official indications limit the medicine's scope to specific allergic conditions. Documentation confirms its intended use for the symptomatic relief of seasonal and perennial allergic conjunctivitis (hay fever eyes) and vernal kerato-conjunctivitis.


Q: Are there any known interactions between Optrex Allergy and common cold medicines?

A: Official regulatory documents state that no specific interactions with other systemic medicines are known for sodium cromoglicate eye drops. However, official information indicates that a healthcare professional should be informed of all concurrent medicines being used.


Q: Is Optrex Allergy known to interact with herbal supplements?

A: Specific interactions with herbal products are not listed in official documents. General regulatory information describes the importance of informing a doctor or pharmacist of all products being used, including any vitamins, minerals, or herbal supplements.


Q: Can people with glaucoma use Optrex Allergy?

A: Glaucoma is not listed in the official contraindications or special warnings for this medicine. Contraindications are limited to known hypersensitivity to the ingredients of the drops.


Q: Can I share my Optrex Allergy eye drops with someone else?

A: Due to the risk of contamination and potential infection, the drops are intended for use by one individual only. Official warnings caution that eye solutions can easily become contaminated by bacteria when handled.


Q: Is Optrex Allergy suitable for someone who has had eye surgery?

A: Official warnings state that in the event of an intercurrent eye condition, such as following ocular surgery or trauma, a physician's advice should be sought. This helps ensure proper assessment of the condition.


Q: Are there any foods or drinks that might interact with Optrex Allergy?

A: Official regulatory documents do not list any known interactions between the eye drops and foods or drinks.


Q: Is the active ingredient in Optrex Allergy commonly used in other countries?

A: Yes, the active ingredient, sodium cromoglicate (also known as cromolyn sodium), is an International Non-proprietary Name (INN). It is widely recognized and used globally in ophthalmic products for allergic conditions.


Q: Is there a generic version of Optrex Allergy available?

A: The active substance in Optrex Allergy is sodium cromoglicate. This substance is available as a generic ophthalmic solution in many markets, often sold under its official generic name.


Q: How does the concentration of the active ingredient in Optrex Allergy compare to prescription versions?

A: Optrex Allergy typically contains a 2% w/v concentration of sodium cromoglicate. Other ophthalmic solutions with the same active ingredient may be available in different concentrations, such as 4%, and these are often classified as prescription-only medicines.


Q: What should I do if my symptoms do not improve after using Optrex Allergy?

A: Official patient information indicates that consultation with a doctor or pharmacist is needed if allergic symptoms do not begin to improve within 48 hours of starting to use the medicine.


Q: Is Optrex Allergy considered a steroid eye drop?

A: No, Optrex Allergy is categorized as a mast cell stabilizer. It is defined in official documents as non-steroidal and does not contain any steroid components.


Q: Why do some people report needing to use it for several days before seeing a major difference?

A: This type of medicine works by preventing the release of allergy-causing chemicals at the cellular level. Official documentation indicates that the full symptomatic benefit may only be fully realized after consistent use over several days or weeks.


Q: Is it required to use Optrex Allergy every day for it to work?

A: For optimal results during allergy season, the medicine is generally recommended for use at regular intervals throughout the day to sustain its preventative effect. Consistent use is advised for achieving the maximum symptomatic benefit.


Q: What happens if I use the drops more frequently than directed on the label?

A: Official warnings note that the recommended frequency of administration is not to be exceeded. In the event of using more than the recommended dose, official sources generally suggest medical observation.


Q: What is the difference between Optrex Allergy and a general lubricating eye drop?

A: Optrex Allergy is classified as a mast cell stabilizer, which is a pharmacological agent that acts at a cellular level to prevent the allergic response. In contrast, a general lubricating drop is a non-medicinal agent intended primarily to moisten the eye's surface.


Q: Is there any evidence suggesting a long-term risk associated with Optrex Allergy?

A: While human long-term safety data for continuous, extended use is generally limited, preclinical studies performed for regulatory review, including chronic toxicity studies in animals, have not raised concerns regarding long-term toxic potential from the medicine.


Q: Why do official documents specify that this drug is not for certain eye infections?

A: The medicine's official indication is limited to the symptomatic relief of allergic eye conditions. The drug is classified as a mast cell stabilizer and does not contain any active ingredients intended to treat or prevent bacterial or viral eye infections.


Q: Can I use Optrex Allergy on an irregular, as-needed basis?

A: The medicine is typically recommended for use at regular intervals throughout the day to sustain its effect. Consistent use is generally advised to maintain the maximum symptomatic benefit, as its mechanism is preventative rather than simply treating symptoms as they appear.

How should Optrex Allergy be stored and disposed of?

Optrex Allergy eye drops should be stored out of the sight and reach of children. Before the bottle is opened, this medicine does not require any special storage conditions. Once opened, do not store the eye drops above 25°C.


To prevent the risk of contamination and infection, the eye drops are sterile when purchased and must not be kept for more than four weeks after the bottle is first opened. Always check the expiry date stated on the bottle label and carton, and do not use the medicine past the last day of that month.


Disposal of this medicine should be done responsibly to protect the environment. Do not dispose of Optrex Allergy via wastewater or household waste. Instead, consult your pharmacist for advice on how to correctly throw away any medicines you no longer use.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Optrex Allergy found in:

A-Z Index: